OVARIAN MUCINOUS ADENOCARCINOMA
Clinical trials for OVARIAN MUCINOUS ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new OVARIAN MUCINOUS ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for OVARIAN MUCINOUS ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Major trial aims to tame dozens of rare, neglected cancers with immune power combo
Disease control OngoingThis study is testing whether a combination of two immunotherapy drugs (nivolumab and ipilimumab) can help control many different types of rare, advanced cancers that have limited treatment options. It enrolled over 800 adults whose cancer progressed after standard therapy. The g…
Matched conditions: OVARIAN MUCINOUS ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 04, 2026 05:21 UTC
-
Doctors test 'Trojan Horse' stem cells carrying Cancer-Killing virus
Disease control OngoingThis early-phase trial is testing a new treatment for ovarian, fallopian tube, or primary peritoneal cancer that has come back after standard therapy. Researchers are using a patient's own fat-derived stem cells to carry a specially engineered measles virus directly to the cancer…
Matched conditions: OVARIAN MUCINOUS ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Apr 04, 2026 05:20 UTC
-
Trial tests weekly vs. standard chemo for Tough-to-Treat cancers
Disease control OngoingThis large study aimed to find out if giving a key chemotherapy drug (paclitaxel) once a week is better than giving it once every three weeks for treating advanced ovarian, fallopian tube, or primary peritoneal cancer. All participants also received another chemotherapy drug (car…
Matched conditions: OVARIAN MUCINOUS ADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC